Minerva Neurosciences Inc

Market Cap

$229M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$4.96+$1.04 (+26.53%)

Jun 5, 2026

52W High $8.0752W Low $1.63

Company Details

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone...

CEO

—

IPO Date

Jul 1, 2014

Website

www.minervaneurosciences.com

Key Metrics TTM

Revenue

-100.0% YoY

Net Income

-$415M

EPS (Diluted)

Free Cash Flow

-$5.4B

Revenue / Share

$0.00

Gross Margin

Operating Margin

Net Margin

FCF Margin

P/S

P/E

Earnings Reports

Q1 2026

May 5, 2026

$0-100.0%

FY 2025

Mar 11, 2026

Q4 2025

Mar 11, 2026

$0-100.0%

Q3 2025

Nov 5, 2025

Q2 2025

Aug 14, 2025

Revenue & Profitability

Valuation

Operating Cash Flow

CapEx Spend

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

War Chest

Shares Outstanding

Revenue Per Employee

Revenue / Employee